Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining the
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-25 7:00 AM EDT | Phio Pharmaceuticals Corp.
Illumisoft Appoints Former White House Chief Healthcare Economist Jonathan Ketcham as Strategic Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) ("Illumisoft" or the "Company") today announced the appointment of Jonathan Ketcham as a strategic advisor to the Company. Dr. Ketcham brings deep expertise in healthcare economics, public policy, reimbursement, procurement, and technology adoption. His guidance is expected to benefit Illumisoft greatly as it advances its ultraviolet germicidal technology platform toward commercializati
Technology, Biotechnology, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-06-25 7:00 AM EDT | Illumisoft Lighting Corporation
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - June 24, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-24 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, today announced a major operational milestone that underscores the strength of Canadian life sciences innovation. Coinciding with the global spotlight on Canadian medical innovation taking the stage at the BIO Int
Technology, Biotechnology, Healthcare and Hospitals
2026-06-23 8:30 AM EDT | BioMark Diagnostics, Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026
Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2026 year-end financial results on Monday, June 29, 2026. Elite's management will host a live conference call on Tuesday, June 30th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. St
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-23 7:00 AM EDT | Elite Pharmaceuticals, Inc.
Richards Group Inc. Announces June 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended June 30, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on June 30, 2026 and will be payable on July 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends a
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-06-19 11:14 AM EDT | Richards Group Inc.
Veritas Association Management Expands Strategic Planning Services for Healthcare Associations
Chicago, Illinois--(Newsfile Corp. - June 18, 2026) - Veritas Association Management, a leading association management company serving healthcare and medical specialty organizations, has expanded its service offerings to include strategic planning and board facilitation services designed specifically for healthcare associations. The new service helps boards and leadership teams develop actionable strategic roadmaps while navigating the rapidly changing healthcare environment, including
2026-06-18 2:43 PM EDT | Veritas Association Management
Envoy Medical to Present at Investor Conferences on June 25th
White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026. Life Sciences Virtual Investor Forum
Biotechnology, Healthcare and Hospitals
2026-06-18 8:30 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-18 7:00 AM EDT | Phio Pharmaceuticals Corp.
Altus Copper Applies for Partial Revocation of Failure-to-File Cease Trade Order, Announces Proposed Financing and Provides Further Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Altus Copper Corp. (the "Company") announces that it has applied to the British Columbia Securities Commission (the "BCSC") and the Ontario Securities Commission (the "OSC") for a partial revocation order (the "Partial Revocation Order") of the failure-to-file cease trade order jointly issued by the BCSC and the OSC on December 5, 2023 (the "FFCTO"). The Company further announces a proposed fina
Food / Beverages, Healthcare and Hospitals, Health
2026-06-17 5:30 PM EDT | Altus Copper Corp.
WELL Health Announces Voting Results for Election of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that at its annual general and special meeting held June 16, 2026 (the "Meeting"), all of the nominees for election as directors of the Compa
Technology, Computer Software, Healthcare and Hospitals, Health
2026-06-17 7:00 AM EDT | WELL Health Technologies Corp.
HEALWELL AI Provides Corporate Update: Multi-Province AI Pilot Results Accepted at AMIA Symposium; Alongside Balance Sheet Strengthening with SpaceX Holdings
HEALWELL successfully completed a pilot evaluating its DARWEN™ AI powered SMART Summary™ and SMART Search™ solutions in multiple provinces across Canada. The pilot demonstrated how clinically validated and interoperable AI can reduce chart review burden, improve access to patient information and support more efficient clinical workflows. HEALWELL is exploring opportunities to expand deployment of its SMART products across additional h
Technology, Healthcare and Hospitals
2026-06-17 3:15 AM EDT | HEALWELL AI
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-16 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Adia Med Improves Quality of Care with Advanced Ultrasound-Guided IV Training
Winter Park, Florida--(Newsfile Corp. - June 16, 2026) - Adia Med, the regenerative medicine and advanced IV therapy division of Adia Nutrition Inc. (OTCQB: ADIA), today announced a major step forward in patient care quality. Renowned physician Dr. Brian Browning, DO, Lead Physician at Adia Med, will personally train the company's Advanced Practice Registered Nurses (APRNs) and Registered Nurses (RNs) in ultrasound-guided intravenous (IV) insertions and administrations using the innovative Bu
Healthcare and Hospitals, Health
2026-06-16 10:55 AM EDT | Adia Nutrition Inc.
TelyRx Announces Voting Results from Annual General Meeting of Shareholders
Clearwater, Florida--(Newsfile Corp. - June 15, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, announced today that each of the following nominees proposed to be elected at the Annual Meeting of Shareholders held on Monday, June 15, 2026 (the "Meeting"), has been elected. In addition, the other resolution put to vote at the Meeting was passed.
Healthcare and Hospitals, Health
2026-06-15 6:57 PM EDT | TelyRx
Extendicare Announces June 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - June 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of June 2026, which is payable on July 15, 2026 to shareholders of record at the close of business on June 30, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare Extendicare i
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-15 8:00 AM EDT | Extendicare Inc.
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Northvale, New Jersey--(Newsfile Corp. - June 15, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product. IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million.
Healthcare and Hospitals, Pharmaceuticals, Health
2026-06-15 7:00 AM EDT | Elite Pharmaceuticals, Inc.
Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany
Ireland and Heppenheim, Germany--(Newsfile Corp. - June 15, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the launch of its innovative acne cream Winlevi® (clascoterone 1% cream) in Austria and Germany by its commercial partner InfectoPharm Arzneimittel und Consilium GmbH (“InfectoPharm”). Winlevi® is available in both countries since June 1. Cosmo is the exclusive manufacturer of the product.
Healthcare and Hospitals, Health
2026-06-15 1:01 AM EDT | Cosmo Pharmaceuticals N.V.
Bachem Holding AG Announces Capital Markets Day 2026
Bubendorf, Switzerland--(Newsfile Corp. - June 12, 2026) - Bachem Holding AG (SIX: BANB) will host its Capital Markets Day on 26 November 2026 at The Circle Convention Center, Hyatt Regency Zurich Airport, as well as virtually. This hybrid event will provide insights into the company's strategic priorities, business outlook, and key developments.
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-06-12 11:47 AM EDT | Bachem Holding AG
Healthcare Special Opportunities Fund Announces June 2026 Quarterly Distribution
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - LDIC Inc. (the "Manager"), the manager of Healthcare Special Opportunities Fund (TSX: MDS.UN) (the "Fund"), a closed-end investment fund, today announces the quarterly distribution of CDN$0.05923 per Class A unit and US$0.05261 per Class U unit. The distribution will be paid on or before July 10, 2026, to unitholders of record on June 30, 2026. For further information pleas
Banking / Financial Services, Healthcare and Hospitals
2026-06-12 10:29 AM EDT | Healthcare Special Opportunities Fund